Published in Nature on August 04, 2005
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature (2007) 16.95
Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol (2008) 11.43
Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer (2009) 11.25
Senescence of activated stellate cells limits liver fibrosis. Cell (2008) 8.98
The essence of senescence. Genes Dev (2010) 8.21
The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol (2010) 7.58
A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell (2006) 6.96
Four faces of cellular senescence. J Cell Biol (2011) 6.86
Senescence in tumours: evidence from mice and humans. Nat Rev Cancer (2010) 6.34
Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell (2008) 5.34
Erasing the methyl mark: histone demethylases at the center of cellular differentiation and disease. Genes Dev (2008) 5.25
Senescence-messaging secretome: SMS-ing cellular stress. Nat Rev Cancer (2009) 5.02
Profile of histone lysine methylation across transcribed mammalian chromatin. Mol Cell Biol (2006) 5.01
T-helper-1-cell cytokines drive cancer into senescence. Nature (2013) 4.47
Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell (2009) 4.30
Genome-wide chromatin state transitions associated with developmental and environmental cues. Cell (2013) 3.83
Inflammatory networks during cellular senescence: causes and consequences. Trends Mol Med (2010) 3.79
BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature (2011) 3.63
A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J Clin Invest (2010) 3.47
Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Invest (2013) 3.47
Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. Cancer Cell (2007) 3.44
Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci U S A (2007) 3.37
The matricellular protein CCN1 induces fibroblast senescence and restricts fibrosis in cutaneous wound healing. Nat Cell Biol (2010) 3.29
Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br J Cancer (2006) 3.23
Short telomeres limit tumor progression in vivo by inducing senescence. Cancer Cell (2007) 3.23
Tailoring to RB: tumour suppressor status and therapeutic response. Nat Rev Cancer (2008) 3.16
Accumulation of senescent cells in mitotic tissue of aging primates. Mech Ageing Dev (2006) 3.14
Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature (2010) 3.09
Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci U S A (2009) 3.08
Telomeric DNA damage is irreparable and causes persistent DNA-damage-response activation. Nat Cell Biol (2012) 3.03
Mitochondrial dysfunction accounts for the stochastic heterogeneity in telomere-dependent senescence. PLoS Biol (2007) 2.78
Interplay between oncogene-induced DNA damage response and heterochromatin in senescence and cancer. Nat Cell Biol (2011) 2.69
The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci U S A (2006) 2.64
JAK signaling globally counteracts heterochromatic gene silencing. Nat Genet (2006) 2.57
Molecular dissection of formation of senescence-associated heterochromatin foci. Mol Cell Biol (2007) 2.56
Telomere dysfunction and tumour suppression: the senescence connection. Nat Rev Cancer (2008) 2.54
A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell (2008) 2.48
Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat Rev Immunol (2009) 2.44
A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency. Mol Cell (2009) 2.41
Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis. Mol Cell (2011) 2.40
Loss of miRNA biogenesis induces p19Arf-p53 signaling and senescence in primary cells. J Cell Biol (2008) 2.39
HIF1alpha delays premature senescence through the activation of MIF. Genes Dev (2006) 2.37
Cellular senescence and its effector programs. Genes Dev (2014) 2.37
Reciprocal regulation of p53 and malic enzymes modulates metabolism and senescence. Nature (2013) 2.29
p21 transcription is regulated by differential localization of histone H2A.Z. Genes Dev (2007) 2.21
ATR signaling can drive cells into senescence in the absence of DNA breaks. Genes Dev (2008) 2.17
Histone lysine demethylases as targets for anticancer therapy. Nat Rev Drug Discov (2013) 2.16
Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras. Proc Natl Acad Sci U S A (2008) 2.14
Mitotic chromosome condensation mediated by the retinoblastoma protein is tumor-suppressive. Genes Dev (2010) 2.12
Dynamic assembly of chromatin complexes during cellular senescence: implications for the growth arrest of human melanocytic nevi. Aging Cell (2007) 2.07
Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev (2007) 1.98
Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by initiating p53-dependent cellular senescence. EMBO Rep (2007) 1.96
Remodeling of chromatin structure in senescent cells and its potential impact on tumor suppression and aging. Gene (2007) 1.92
Cellular senescence and organismal aging. Mech Ageing Dev (2008) 1.92
Cancer: crime and punishment. Nature (2005) 1.91
Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer. Nature (2014) 1.88
Downregulation of Wnt signaling is a trigger for formation of facultative heterochromatin and onset of cell senescence in primary human cells. Mol Cell (2007) 1.87
Canonical and non-canonical JAK-STAT signaling. Trends Cell Biol (2008) 1.85
The interaction between Myc and Miz1 is required to antagonize TGFbeta-dependent autocrine signaling during lymphoma formation and maintenance. Genes Dev (2010) 1.81
miR-22 represses cancer progression by inducing cellular senescence. J Cell Biol (2011) 1.78
Connections between epigenetic gene silencing and human disease. Mutat Res (2007) 1.72
Oncogene-induced telomere dysfunction enforces cellular senescence in human cancer precursor lesions. EMBO J (2012) 1.71
Mechanisms controlling cell cycle exit upon terminal differentiation. Curr Opin Cell Biol (2007) 1.70
Chemotherapeutic approaches for targeting cell death pathways. Oncologist (2006) 1.70
Opposing roles of NF-κB in anti-cancer treatment outcome unveiled by cross-species investigations. Genes Dev (2011) 1.69
CPEB regulation of human cellular senescence, energy metabolism, and p53 mRNA translation. Genes Dev (2008) 1.66
Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. Nature (2013) 1.66
Implications of cellular senescence in tissue damage response, tumor suppression, and stem cell biology. Cold Spring Harb Symp Quant Biol (2009) 1.64
Definition of pRB- and p53-dependent and -independent steps in HIRA/ASF1a-mediated formation of senescence-associated heterochromatin foci. Mol Cell Biol (2007) 1.62
The miR-17-92 cluster of microRNAs confers tumorigenicity by inhibiting oncogene-induced senescence. Cancer Res (2010) 1.60
Skin epidermis lacking the c-Myc gene is resistant to Ras-driven tumorigenesis but can reacquire sensitivity upon additional loss of the p21Cip1 gene. Genes Dev (2006) 1.60
Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. J Clin Invest (2007) 1.59
Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer. Cancer Res (2008) 1.58
Oncogene-induced senescence results in marked metabolic and bioenergetic alterations. Cell Cycle (2012) 1.57
Systems biology of ageing and longevity. Philos Trans R Soc Lond B Biol Sci (2011) 1.52
A genome-wide RNA interference screen identifies putative chromatin regulators essential for E2F repression. Proc Natl Acad Sci U S A (2007) 1.50
Histone demethylase JMJD2B functions as a co-factor of estrogen receptor in breast cancer proliferation and mammary gland development. PLoS One (2011) 1.48
Deregulation of oncogene-induced senescence and p53 translational control in X-linked dyskeratosis congenita. EMBO J (2010) 1.47
Control of cellular senescence by CPEB. Genes Dev (2006) 1.47
Crosstalk between chromatin state and DNA damage response in cellular senescence and cancer. Nat Rev Cancer (2012) 1.45
Chromosomal breakpoints in primary colon cancer cluster at sites of structural variants in the genome. Cancer Res (2008) 1.44
FoxO transcription factors suppress Myc-driven lymphomagenesis via direct activation of Arf. Genes Dev (2007) 1.43
Oncogenic RAS regulates BRIP1 expression to induce dissociation of BRCA1 from chromatin, inhibit DNA repair, and promote senescence. Dev Cell (2011) 1.43
Obesity increases vascular senescence and susceptibility to ischemic injury through chronic activation of Akt and mTOR. Sci Signal (2009) 1.43
MicroRegulators come of age in senescence. Trends Genet (2011) 1.42
ATM-Chk2-p53 activation prevents tumorigenesis at an expense of organ homeostasis upon Brca1 deficiency. EMBO J (2006) 1.38
Lysosome-mediated processing of chromatin in senescence. J Cell Biol (2013) 1.38
MYC through miR-17-92 suppresses specific target genes to maintain survival, autonomous proliferation, and a neoplastic state. Cancer Cell (2014) 1.36
Cellular senescence controls fibrosis in wound healing. Aging (Albany NY) (2010) 1.36
p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells. J Exp Med (2013) 1.34
Senescent cells harbour features of the cancer epigenome. Nat Cell Biol (2013) 1.34
The atypical E2F family member E2F7 couples the p53 and RB pathways during cellular senescence. Genes Dev (2012) 1.33
Chromatin structure as a mediator of aging. FEBS Lett (2010) 1.33
Regulation of ploidy and senescence by the AMPK-related kinase NUAK1. EMBO J (2009) 1.33
Human papillomavirus E7 repression in cervical carcinoma cells initiates a transcriptional cascade driven by the retinoblastoma family, resulting in senescence. J Virol (2006) 1.33
Cellular features of senescence during the evolution of human and murine ductal pancreatic cancer. Oncogene (2011) 1.32
A molecular signature predictive of indolent prostate cancer. Sci Transl Med (2013) 1.32
Inhibition of SUV39H1 methyltransferase activity by DBC1. J Biol Chem (2009) 1.31
The M-type receptor PLA2R regulates senescence through the p53 pathway. EMBO Rep (2009) 1.29
Global reorganization of the nuclear landscape in senescent cells. Cell Rep (2015) 1.28
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med (2008) 13.02
Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing. Genes Dev (2005) 12.15
Partitioning and plasticity of repressive histone methylation states in mammalian chromatin. Mol Cell (2003) 11.33
A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet (2007) 9.47
Suv39h-mediated histone H3 lysine 9 methylation directs DNA methylation to major satellite repeats at pericentric heterochromatin. Curr Biol (2003) 9.13
A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive heterochromatin. Genes Dev (2004) 8.66
LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature (2005) 8.53
Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet (2005) 8.45
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood (2011) 7.43
A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med (2006) 7.42
Establishment of histone h3 methylation on the inactive X chromosome requires transient recruitment of Eed-Enx1 polycomb group complexes. Dev Cell (2003) 7.11
The profile of repeat-associated histone lysine methylation states in the mouse epigenome. EMBO J (2005) 7.10
A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell (2002) 6.76
The many faces of histone lysine methylation. Curr Opin Cell Biol (2002) 6.01
Higher-order structure in pericentric heterochromatin involves a distinct pattern of histone modification and an RNA component. Nat Genet (2002) 5.86
Central role of Drosophila SU(VAR)3-9 in histone H3-K9 methylation and heterochromatic gene silencing. EMBO J (2002) 5.70
Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease. J Exp Med (2007) 5.52
Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell (2007) 5.49
Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J (2002) 5.33
Different EZH2-containing complexes target methylation of histone H1 or nucleosomal histone H3. Mol Cell (2004) 5.06
Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. Blood (2010) 4.99
Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med (2010) 4.76
Maintenance of stable heterochromatin domains by dynamic HP1 binding. Science (2003) 4.74
p53 is regulated by the lysine demethylase LSD1. Nature (2007) 4.53
Repression of p53 activity by Smyd2-mediated methylation. Nature (2006) 4.51
An epigenetic road map for histone lysine methylation. J Cell Sci (2003) 4.43
A chromosomal memory triggered by Xist regulates histone methylation in X inactivation. PLoS Biol (2004) 4.23
Recruitment of PRC1 function at the initiation of X inactivation independent of PRC2 and silencing. EMBO J (2006) 4.16
Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med (2003) 3.99
Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. Nat Cell Biol (2007) 3.89
Mutant nuclear lamin A leads to progressive alterations of epigenetic control in premature aging. Proc Natl Acad Sci U S A (2006) 3.86
Epigenetic regulation of telomere length in mammalian cells by the Suv39h1 and Suv39h2 histone methyltransferases. Nat Genet (2003) 3.64
Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Res (2006) 3.59
Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science (2005) 3.58
Dual histone H3 methylation marks at lysines 9 and 27 required for interaction with CHROMOMETHYLASE3. EMBO J (2004) 3.51
Histone H3 lysine 9 methylation is an epigenetic imprint of facultative heterochromatin. Nat Genet (2001) 3.46
TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood (2011) 3.32
Jmjd2b antagonizes H3K9 trimethylation at pericentric heterochromatin in mammalian cells. Genes Dev (2006) 3.24
Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol (2011) 3.17
Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. Cancer Cell (2007) 3.16
A chromatin-wide transition to H4K20 monomethylation impairs genome integrity and programmed DNA rearrangements in the mouse. Genes Dev (2008) 3.16
Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia. J Clin Oncol (2011) 3.09
H3K27me3 forms BLOCs over silent genes and intergenic regions and specifies a histone banding pattern on a mouse autosomal chromosome. Genome Res (2008) 3.09
Su(var) genes regulate the balance between euchromatin and heterochromatin in Drosophila. Genes Dev (2004) 3.08
Repressive and active histone methylation mark distinct promoters in human and mouse spermatozoa. Nat Struct Mol Biol (2010) 3.07
MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood (2013) 3.03
Dimethylation of histone H3 lysine 9 is a critical mark for DNA methylation and gene silencing in Arabidopsis thaliana. Chromosoma (2004) 3.00
Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med (2010) 2.97
Polycomb group proteins Ezh2 and Rnf2 direct genomic contraction and imprinted repression in early mouse embryos. Dev Cell (2008) 2.96
Consequences of the depletion of zygotic and embryonic enhancer of zeste 2 during preimplantation mouse development. Development (2003) 2.91
TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol (2011) 2.88
High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood (2006) 2.87
Whipple's disease: new aspects of pathogenesis and treatment. Lancet Infect Dis (2008) 2.78
Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology (2005) 2.78
Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. Cancer Res (2009) 2.75
In vivo control of CpG and non-CpG DNA methylation by DNA methyltransferases. PLoS Genet (2012) 2.70
Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood (2012) 2.69
Active and repressive chromatin are interspersed without spreading in an imprinted gene cluster in the mammalian genome. Mol Cell (2007) 2.69
Silencing by plant Polycomb-group genes requires dispersed trimethylation of histone H3 at lysine 27. EMBO J (2006) 2.68
Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood (2008) 2.66
Heterochromatin formation in Drosophila is initiated through active removal of H3K4 methylation by the LSD1 homolog SU(VAR)3-3. Mol Cell (2007) 2.66
G9a and Glp methylate lysine 373 in the tumor suppressor p53. J Biol Chem (2010) 2.64
Intestinal non-Hodgkin's lymphoma: a multicenter prospective clinical study from the German Study Group on Intestinal non-Hodgkin's Lymphoma. J Clin Oncol (2003) 2.54
The microRNA miR-182 is induced by IL-2 and promotes clonal expansion of activated helper T lymphocytes. Nat Immunol (2010) 2.53
Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol (2010) 2.38
PRC1 and Suv39h specify parental asymmetry at constitutive heterochromatin in early mouse embryos. Nat Genet (2008) 2.37
Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma. Nat Immunol (2005) 2.31
Interleukin (IL)-23 mediates Toxoplasma gondii-induced immunopathology in the gut via matrixmetalloproteinase-2 and IL-22 but independent of IL-17. J Exp Med (2009) 2.28
Role of the RB1 family in stabilizing histone methylation at constitutive heterochromatin. Nat Cell Biol (2005) 2.27
Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol (2011) 2.26
Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer (2011) 2.25
Suv4-20h deficiency results in telomere elongation and derepression of telomere recombination. J Cell Biol (2007) 2.24
Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia. J Clin Oncol (2009) 2.23
Histone demethylase UTX-1 regulates C. elegans life span by targeting the insulin/IGF-1 signaling pathway. Cell Metab (2011) 2.22
Novel murine infection models provide deep insights into the "ménage à trois" of Campylobacter jejuni, microbiota and host innate immunity. PLoS One (2011) 2.20
Localized H3K36 methylation states define histone H4K16 acetylation during transcriptional elongation in Drosophila. EMBO J (2007) 2.19
Mucosal but not peripheral FOXP3+ regulatory T cells are highly increased in untreated HIV infection and normalize after suppressive HAART. Blood (2006) 2.19
Cutting edge: depletion of Foxp3+ cells leads to induction of autoimmunity by specific ablation of regulatory T cells in genetically targeted mice. J Immunol (2009) 2.17
Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature. Gynecol Oncol (2005) 2.15
Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL. Cancer Cell (2012) 2.15
A transcription factor-based mechanism for mouse heterochromatin formation. Nat Struct Mol Biol (2012) 2.15
Epigenetic marking correlates with developmental potential in cloned bovine preimplantation embryos. Curr Biol (2003) 2.14
Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol (2009) 2.13
RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. J Clin Oncol (2011) 2.11
Persistent malignant stem cells in del(5q) myelodysplasia in remission. N Engl J Med (2010) 2.11
Generation and characterization of methyl-lysine histone antibodies. Methods Enzymol (2004) 2.09
A Bruno-like gene is required for stem cell maintenance in planarians. Dev Cell (2006) 2.08